Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Mereo BioPharma Group plc - Sponsored ADR (MREO) had Return on Tangible Equity of -18.20% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-7.35M |
|
$0.00M |
|
$-0.00M |
|
$8.09M |
|
$-8.09M |
|
$0.74M |
|
$-7.35M |
|
$-7.35M |
|
$-7.35M |
|
$-7.35M |
|
$-7.35M |
|
$-7.35M |
|
$-8.09M |
|
$-7.63M |
|
159.42M |
|
159.42M |
|
$-0.04 |
|
$-0.04 |
|
| Balance Sheet Financials | |
$45.02M |
|
$0.14M |
|
$0.90M |
|
$45.92M |
|
$4.30M |
|
-- |
|
$0.70M |
|
$5.00M |
|
$40.92M |
|
$40.40M |
|
$40.92M |
|
159.13M |
|
| Cash Flow Statement Financials | |
$-30.97M |
|
$-0.02M |
|
$0.33M |
|
$69.80M |
|
$40.99M |
|
$-28.81M |
|
$7.60M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.46 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-30.99M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-17.97% |
|
|
Return on Tangible Equity |
-18.20% |
-16.01% |
|
-17.97% |
|
$0.26 |
|
$-0.19 |
|
$-0.19 |
|